Session Information
Session Title: Pediatric Rheumatology-Clinical and Therapeutic Aspects III: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Session Type: Abstract Submissions (ACR)
Background/Purpose: Juvenile Systemic Sclerosis (JSS) is characterized by Raynaud`s phenomenon (RP) and digital ulcers (DU).Conventional therapy includes calcium channel blockers (CCB). A growing number of vasodilators is available for treatment of refractory patients but there is no clear evidence of the best option. To aid clinical decision-making, an expert consensus was undertaken. Our objective was to identify the best therapeutic options and define the sequence of 2nd line vasodilators for RP and DU.
Methods: Steps in the process of consensus were: a) Identification of expert panel (EP) members, b) Identification of 2nd line vasodilators c) selection of outcome measures to define RP and DU improvement, d) systematic literature review; e) summary report of the latest scientific evidence f) expert consensus meeting; g) rating of the strength of evidence. RAND/UCLA appropriateness method was used for rating the medical decision: items were rated on a 9-point scale for each drug option. There were 2 scoring rounds: 1) anonymous and independent rating of the appropriateness of vasodilators based on scientific evidence and best clinical judgment. 2) Differences in scoring were discussed at a face-to-face meeting in a second rating round. Consensus was reached on appropriate / inappropriateness.
Results: The EP included 10 physicians from a tertiary center who are involved in the care of patients with JSS: 3 pediatric rheumatologists, 2 dermatologists, 1 pediatrician, 1 gastroenterologist, 1 nephrologist, 1 nutricionist, 1 pharmacologist, and a moderator. The EP identified 4 drugs for analysis: bosentan, iloprost, sildenafil, and trepostinil. Outcome measures were selected according to the literature references and EP judgment. RP improvement definition: ≥ 30% improvement according to the physician (in a visual analogue scale, VAS) and ≥ 30 % improvement in at least 2 patient-related domains (pain or function). Patient domains were: a) number of episodes, b) pain in a VAS, c) function (impaired activity of daily living, VAS), d) RP episodes average duration (in minutes). DU improvement definition: a favorable change in all physician- and patient-related domains: patient’s domains: a) pain (VAS) b) function (VAS); physician´s domains: a) ulcer activity (VAS) b) horizontal and transverse DU diameter (in mm). Systematic literature review was performed independently by 5 EP members and guided by the moderator. All articles in English were eligible. Data bases included PuBmed and Cochrane. The search strategy included all relevant terms: bosentan, iloprost, sildenafil, trepostinil, RP, DU, combined in different sets of keywords. The summary report of the scientific evidence included 25 articles. Ranking of papers according to the strength of evidence showed: 1a (1 paper), 1b (7), 2b (2), 3b (2), 4(8), 5(5). After second scoring round consensus was reached: 1st appropriate indication Iloprost; 2nd bosentan, 3rd sildenafil; 4th trepostinil.
Conclusion: The EP reached a consensus on vasodilator drugs, providing direction for common dilemmas in the pharmacologic treatment of RP and DU in refractory patients.
Disclosure:
M. M. Katsicas,
None;
M. Gonzalez,
None;
R. A. G. Russo,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/consensus-what-agent-to-use-when-first-line-vasodilatadors-fail-in-raynauds-phenomenon-or-digital-ulcers-secondary-to-juvenile-systemic-sclerosis/